This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Dr. Stefanou et al. analyzed the risk of acute ischemic stroke (AIS) after COVID-19 vaccination and its potential association with thrombotic-thrombocytopenia syndrome (TTS) in a systematic review and meta-analysis of 2 randomized-controlled trials (RCTs), 3 cohort studies, and 11 registry-based studies. They found 17,481 AIS cases among 782,989,363 COVID-19 vaccinations, giving a pooled proportion of postvaccination AIS of 4.7 cases per 100,000 vaccinations, with no difference observed between mRNA-based and adenovirus-based vaccinations. The pooled proportion of TTS in AIS cases was 3.1%. In response, Dr. Du notes that the rate of AIS cases was lower than the age-standardized global AIS prevalence and incidence rates per 100,000 individuals per year, suggesting that the vaccinations may be associated with a lower risk of AIS. In this regard, Dr. Du cites a previous study that found a significant association between COVID-19 vaccination and lower risks of myocardial infarction and ischemic stroke. Responding to these comments, the authors caution that their crude estimate of new AIS events per 100,000 vaccination, without age standardization or annualization, was not directly comparable with age-standardized AIS estimates per 100,000 individuals per year in the general population. These exchange raises demonstrate relevant complexities when seeking to compare the risk of postvaccination AIS with the “background” risk in the general population while motivating additional studies to investigate whether COVID-19 vaccination might reduce AIS risk at a population level.
Dr. Stefanou et al. analyzed the risk of acute ischemic stroke (AIS) after COVID-19 vaccination and its potential association with thrombotic-thrombocytopenia syndrome (TTS) in a systematic review and meta-analysis of 2 randomized-controlled trials (RCTs), 3 cohort studies, and 11 registry-based studies. They found 17,481 AIS cases among 782,989,363 COVID-19 vaccinations, giving a pooled proportion of postvaccination AIS of 4.7 cases per 100,000 vaccinations, with no difference observed between mRNA-based and adenovirus-based vaccinations. The pooled proportion of TTS in AIS cases was 3.1%. In response, Dr. Du notes that the rate of AIS cases was lower than the age-standardized global AIS prevalence and incidence rates per 100,000 individuals per year, suggesting that the vaccinations may be associated with a lower risk of AIS. In this regard, Dr. Du cites a previous study that found a significant association between COVID-19 vaccination and lower risks of myocardial infarction and ischemic stroke. Responding to these comments, the authors caution that their crude estimate of new AIS events per 100,000 vaccination, without age standardization or annualization, was not directly comparable with age-standardized AIS estimates per 100,000 individuals per year in the general population. These exchange raises demonstrate relevant complexities when seeking to compare the risk of postvaccination AIS with the “background” risk in the general population while motivating additional studies to investigate whether COVID-19 vaccination might reduce AIS risk at a population level.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- Received December 29, 2022.
- Accepted in final form December 29, 2022.
- © 2023 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
